Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia.
By Brian J. Druker, N. Lydon. Journal of Clinical Investigation, 2000
897 citations recorded by the source corpus.
Subfields: Genetics, Hematology, Oncology
View Paper: https://www.semanticscholar.org/paper/22b63ad851dbf659e7864c02f991ab3ff337fc8d
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Genetics
In Hematology
In Oncology
Citations in the corpus
- In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. (2003, methodology): “In particular, we have investigated the use of a noninvasive imaging technology, the Xenogen in vivo imaging system (25), to monitor antitumor effects in individual mice throughout the course of a study.”
- Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study. (2002, neutral): “Median age, y (range) 56 (19-81) 57 (19-81) 52 (20-73) 56 (19-81)”
- Clinical Pharmacokinetics of Imatinib (2005, neutral): “[20]”
- Structure-based Systems Biology for Analyzing Off-target Binding (2011, background): “[8]) or discovered serendipitously but not rationally for a single molecule, for example, imatinib [9,10] and lipitor [11].”
- The role of FLT3 in haematopoietic malignancies (2003, background): “FLT3 inhibitors After the success of imatinib (Glivec; Novartis) — a small-molecule tyrosine-kinase inhibitor (TKI) used to treat CM”
- Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. (2002, neutral): “Median (range) 57 (22-86) 56 (25-86) 58 (22-80) 56 (22-86)”
- Implications of the Human Genome Project for medical science. (2001, positive): “A gratifying recent example is the development of the drug STI-571,whichwasdesigned toblock the kinase activity of the bcr-abl kinase.(20) This protein is produced as a consequence of the translocation between chromosomes 9 and 22, a chromosome rearrangement that is characteristic of and central to ”